Health data processing with no sector-specific regulator or data-protection standard to lean on — data minimisation and purpose limitation have to do the work themselves.
Unlike BFSI, there is no sector regulator or standard governing health-data handling specifically — disciplined data minimisation and purpose limitation become the primary safeguard, not a supplementary one.
Genuine Legitimate Uses but must be applied narrowly and documented precisely — e.g. reporting an HIV-positive diagnosis to the designated authority before releasing a sample, or confirming PCPNDT Act compliance before a prenatal ultrasound.
Consent requirements differ by procedure and by provider — there is no single standard consent flow; each clinical scenario needs its own tailored consent design and language.
Research and clinical trial data requires an entirely separate, more rigorous consent standard from routine care — the two should never share a template.
Sharing between hospitals, diagnostic labs and referring physicians is operationally necessary for continuity of care, and needs proper Data Processor/Fiduciary terms rather than informal exchange.
Patient rights requests (access, correction) intersect with medical-record retention obligations under other laws.
Mainly EHR/EMR platform vendors, plus general industry-agnostic processors (cloud, CRM) rather than a large specialised ecosystem like BFSI's.
The real risk concentrates at the doorstep/final step of care delivery — home sample collection, report delivery, field visits — which, like BFSI's last mile, is predominantly run over WhatsApp, an unsecured channel for patient data.
30 minutes to talk through your specific data footprint — no obligation.
Book a Consultation